Contact Pfizer Media Relations
This information is intended for media professionals.
This information is intended for media professionals only. To ensure that customers, investors, and others receive the appropriate attention, Pfizer media contacts may ONLY respond to calls and emails from professional journalists.
If you are not a journalist, please visit the Contact Page and consult the appropriate Pfizer contact.
Phone: (212) 573-1226
For specific media inquiries:
Europe/Africa/Middle East, email wwce@pfizer.com
You can also visit our Pfizer Worldwide Web Sites.
| Contact |
Responsibility |
Key Focus Areas / Issues (Not all-inclusive) |
|---|---|---|
Ray Kerins W: 212-733-9203 C: 917-324-0080 Ray.Kerins@pfizer.com |
Vice President, External Affairs & Worldwide Communications | |
![]() Chris Loder W: 212-733-7897 C: 347-453-8199 Christopher.Loder@pfizer.com |
Head of Media Relations - United States | Litigation; Counterfeiting; Oncology |
![]() Anne Wilson W: 212-733-5017 C: 202-297-7661 Anne.E.Wilson@pfizer.com |
Head Medical & Science Media Relations | |
![]() Kristen Neese W: 212-733-8926 C: 646-299-2526 Kristen.E.Neese@pfizer.com |
Head Regulatory & Policy Media Relations | |
| Joan Campion W: 212-733-2798 C: 201-761-9384 Joan.Campion@pfizer.com |
Corporate/Financial Media Relations | Finance; Earnings/SEC Filings; Corporate Governance; Business Development |
| Sally Beatty W: 212-733-6566 C: 347-330-7867 Sally.Beatty@pfizer.com |
Primary Care | Lipitor, Viagra, Chantix |
![]() Mackay Jimeson W: 212-733-2324 C: 347-439-5647 Mackay.Jimeson@pfizer.com |
Primary Care | Lyrica, Celebrex, Spiriva, Toviaz, Dimebon, Apixiban, Tanezumab |
![]() Gwen Fisher W: 484-865-5160 C: 215-407-1548 Gwen.Fisher@pfizer.com |
Specialty Care | Prevnar, Prevenar 13, Tygacil, Revatio, Geodon, Enbrel, JAK-3 inhibitors |
Rick ChambersW: 269-833-6387 C:269-760-0770 Richard.T.Chambers@pfizer.com |
GGlobal Manufacturing; Global Engineering; U.S. Regional Support | Environmental; Manufacturing sites |
![]() Liz Power W: 860-732-4987 C: 860-501-3849 Elizabeth.Power@pfizer.com |
PGRD | Medical and Science Communications |
![]() Rick Goulart W: 212-733-7457 C: 860-501-3391 Rick.Goulart@pfizer.com |
Animal Health | |
![]() Samantha Cummis W: 212-733-6924 C: 917-679-8413 Samantha.Cummis@pfizer.com |
Business Development, Strategy & Innovation | |
![]() Andrew Topen W: 44 1737 332236 C: 44 7967 757688 Andrew.Topen@pfizer.com |
Head EU Media Relations | |
| Monica Pinuela W: 34 91 490 99 20 C: 34 647 37 62 85 Monica.Pinuela@pfizer.com |
Europe | R&D/science; Product Communications |
![]() Tyrene Frederick-Mack W: 212-733-3848 C: 917-327-7821 Tyrene.Frederick-Mack@pfizer.com |
Latin America | |
![]() Marco Winkler W: 212-733-9313 C: 646-318-1264 Marco.Winkler@pfizer.com |
Eastern Europe, Middle East, Africa | |
| Neena Moorjani W: 852 2287 9939 C: 852 9038 0150 Neena.Moorjani@pfizer.com |
Asia Pacific |
Stock Quote Disclaimer
20 minute delayed data provided by Comstock. Charts are provided by BigCharts and MarketWatch, Inc. Pfizer makes no claims concerning the accuracy of the information provided on these pages, and will not be held liable for any use of this information. Note: Historical and current stock price performance data is not necessarily indicative of future performance.
Stock Symbol: PFE Stock Exchange: NYSE
Stock Quote at: Mar 9 2010 4:00PM
| Last 17.23 | Change -0.12 |
| %Change | -0.69 | Vol. | 54,551,200 |
| Day High | 17.32 | 52 Wk. High | 20.36 |
| Day Low | 17.15 | 52 Wk. Low | 12.59 |
| Open | 17.27 | Mkt. Cap(Bil) | 139.01 |
| Prev. Close | 17.35 |
Pfizer Annual Review:
Doing Things Differently
We are becoming the Pfizer we are meant to be — one that can offer healthy solutions at every stage of life.





Rick Chambers




